Brokerages Set SUMMIT THERAPEU/S (NASDAQ:SMMT) PT at $2.50
Shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) have been assigned a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $2.17.
Several equities analysts recently commented on SMMT shares. HC Wainwright boosted their price target on Largo Resources from C$5.10 to C$5.20 in a research report on Thursday, March 28th. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Zacks Investment Research upgraded Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Saturday. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a report on Thursday, June 13th. Finally, Oppenheimer set a $10.00 price objective on Motus GI and gave the stock a “buy” rating in a report on Thursday, March 28th.
An institutional investor recently raised its position in SUMMIT THERAPEU/S stock. Acadian Asset Management LLC grew its position in SUMMIT THERAPEU/S (NASDAQ:SMMT) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 183,160 shares of the company’s stock after acquiring an additional 10,208 shares during the quarter. Acadian Asset Management LLC owned approximately 1.32% of SUMMIT THERAPEU/S worth $210,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.75% of the company’s stock.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last released its quarterly earnings results on Wednesday, June 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.11. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $4.34 million. SUMMIT THERAPEU/S had a return on equity of 26.31% and a net margin of 24.32%. On average, sell-side analysts predict that SUMMIT THERAPEU/S will post -1.08 earnings per share for the current fiscal year.
SUMMIT THERAPEU/S Company Profile
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Featured Story: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.